Early esophageal cancer or precancerous lesions treated by endoscopic resection: a single-center retrospective study of 368 cases
10.13315/j.cnki.cjcep.2017.06.004
- VernacularTitle:368例内镜切除早期食管癌及癌前病变回顾性分析
- Author:
Yalan LIU
;
Dongxian JIANG
;
Yingyong HOU
;
Jieakesu SU
;
Haiying ZENG
;
Jie HUANG
;
Yifan XU
;
Chen XU
- Keywords:
esophageal neoplasms;
precancerous lesion;
endoscopic resection;
sm2;
prognosis
- From:
Chinese Journal of Clinical and Experimental Pathology
2017;33(6):606-612
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the clinicopathological features as well as prognosis of early esophageal squamous cell neoplasm (ESCN) treated with endoscopic resection (ER).Methods 368 patients were collected from 2007 to 2013.Clinicopathological features including invasion depth and margin were evaluated.Survival curves were constructed by using the Kaplan-Meier method.Univariate and multivariate Cox proportional hazard regression models were performed to identify associations with outcome variables.Results There were 252 males and 116 females with a median age of 61 (16-84) years.Patient numbers of hyperplasia,low grade intraepithelial neoplasia,high grade intraepithelial neoplasia,m1,m2,m3,sm1 and sm2 were 47(12.8％),61 (16.6％),61 (16.6％),54(14.7％),38(10.3％),63(17.1％),12(3.3％) and 32(8.7％),respectively.The cumulative overall 1-year,3-year,and 5-year rates of survival in the metachronous esophageal lesions were 4.1％,12.9％ and 32.6％,respectively.The incidence of lymph node/distant metastasis was 1.54％ in m3,6.25％ in sm2,and 0 in other subgroups.The overall 1-year,3-year,and 5-year survival rates were 99.5％,97.3％,and 87.5％,respectively.Significant difference was identified between sm2 and non-sm2 patients in metastatic rate (P =0.021),however,no significant difference existed between m3 patients and sm2 patients (P =0.252).Metachronous esophageal lesion and survival between sm2 and non-sm2 patients demonstrated no statistical difference (P =0.401 and P =0.634).Conclusion ER is an effective and relatively safe treatment for superficial ESCN.The procedure is still appropriate in selecting sin2 patients.It is necessary to monitor the second primary cancer in sm2 patients during follow-up.
